Renhe Pharmaceutical (000650pennaffinity3longcast.SZ) announced that the company's subsidiary Jiangxi Yaodu Renhe Pharmaceutical Co., Ltd. recently received approval and issuance from the State Drug Administrationpennaffinity3longcast"Drug Registration Certificate" for oseltamivir phosphate capsules. Oseltamivir phosphate is an influenza virus neuraminidase inhibitor (NAI) that is suitable forpennaffinity3longcast: For the treatment of influenza A and B in adults and children 1 year old and older (oseltamivir phosphate can effectively treat influenza A and B, but there are not many clinical application data on influenza B). Patients should use it within 48 hours of first symptoms. For the prevention of influenza A and B in adults and young people aged 13 and above.
